FDA Announces Final Guidance to Reduce Risk of Creutzfeldt-Jakob Disease Transmission via Blood and Blood Components

Summary

The US Food and Drug Administration (FDA) has released a final guidance document outlining revised recommendations to minimize the risk of transmitting Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD) through blood and blood components, effective immediately.